Specifically, the inhibition of p38 decreased the adhesion of myeloma cells to BMSCs, reduced the myeloma cell proliferation, and shortened the tumor burden in the murine MM model [17, 18]. The gene discussed is MAPK14; the disease is plasma cell myeloma.